Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $100000.0.

  • Vivos Therapeutics' Share-based Compensation changed 0.0% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $812000.0, marking a year-over-year increase of 74.44%. This contributed to the annual value of $800000.0 for FY2024, which is 2766.73% down from last year.
  • Latest data reveals that Vivos Therapeutics reported Share-based Compensation of $100000.0 as of Q3 2025, which was down 0.0% from $300000.0 recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Share-based Compensation ranged from a high of $1.1 million in Q3 2021 and a low of $95000.0 during Q4 2024
  • Moreover, its 5-year median value for Share-based Compensation was $317000.0 (2025), whereas its average is $398842.1.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 15964.45% in 2021, then tumbled by 8632.26% in 2023.
  • Vivos Therapeutics' Share-based Compensation (Quarter) stood at $463000.0 in 2021, then soared by 67.39% to $775000.0 in 2022, then crashed by 86.32% to $106000.0 in 2023, then dropped by 10.38% to $95000.0 in 2024, then grew by 5.26% to $100000.0 in 2025.
  • Its Share-based Compensation was $100000.0 in Q3 2025, compared to $300000.0 in Q2 2025 and $317000.0 in Q1 2025.